查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球生物標誌物市場：按產品/服務(消耗品,服務,軟件),產品(安全性,功效,驗證),疾病(癌症,傳染病,神經系統疾病),應用(診斷,藥物發現,個性化醫療),預測地區至2028
市場調查報告書
商品編碼
1230248

全球生物標誌物市場：按產品/服務(消耗品,服務,軟件),產品(安全性,功效,驗證),疾病(癌症,傳染病,神經系統疾病),應用(診斷,藥物發現,個性化醫療),預測地區至2028

Biomarkers Market by Product & Service (Consumable, Service, Software), Type (Safety, Efficacy, Validation), Disease (Cancer, Infectious, Neurological), Application (Diagnostics, Drug Discovery, Personalized Medicine), Region - Global Forecast to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 246 Pages | 訂單完成後即時交付

價格
簡介目錄

全球生物標誌物市場規模預計將從 2023 年的 591 億美元增長到 2028 年的 1040 億美元，複合年增長率為 12.0%。

市場增長的主要驅動力是診斷的重要性日益增加,癌症和心髒病的患病率增加,生物標誌物研究的資金和贈款增加,持續的產品創新,生物技術標誌物的進步等等。 另一方面，生物標誌物驗證時間長,成本高和分析開發困難等因素阻礙了市場增長。

按疾病和適應症劃分，癌症領域預計在預測期內（2023 年至 2028 年）增長最快。 癌症生物標誌物預計將受到主要製造商與癌症生物標誌物相關的強大產品線的進一步刺激。

從應用來看，2022年診斷領域佔比最大。 隨著慢性病變得越來越普遍，對靶向治療和診斷的需求增加推動了這一領域的增長。 越來越多地使用生物標誌物也推動了診斷領域的發展。

按地區劃分，北美將在 2022 年佔據最大份額。 主要驅動因素包括慢性病患病率上升,生物標誌物在個性化醫療中的使用增加,大公司的各種有機和無機增長戰略，以及生物標誌物應用的擴展和進步。

在本報告中，我們分析了全球生物標誌物市場，包括市場的基本結構,最新情況,驅動和製約市場的主要因素，以及產品/服務,類型,疾病/適應症,應用和我們正在按區域調查市場趨勢的前景,市場競爭狀況以及主要公司的概況。

內容

第一章介紹

第二章研究方法論

第 3 章執行摘要

第 4 章重要注意事項

第 5 章市場概述

  • 市場動態
    • 市場驅動力
    • 約束因素
    • 機會
    • 任務
  • 監管評估
  • 價值鏈分析
  • 技術分析
  • 價格分析
  • 專利分析
  • 生物標誌物市場：供應鏈分析
  • 生態系統分析
  • 主要會議和活動 (2023-2024)
  • 波特的五力分析
  • 主要利益相關者和採購標準
  • 生物標誌物市場的生態系統分析
  • 生物標誌物市場的利潤轉移

第 6 章生物標誌物市場：按產品/服務分類

  • 簡介
  • 消耗品
  • 服務
  • 軟件

第 7 章生物標誌物市場：按類型分類

  • 簡介
  • 功效生物標誌物
    • 預測性生物標誌物
    • 替代生物標誌物
    • 藥效學 (PD) 生物標誌物
    • 預後生物標誌物
  • 安全生物標誌物
  • 驗證生物標誌物

第 8 章生物標誌物市場：按疾病/適應症分類

  • 簡介
  • 癌症
  • 感染
  • 免疫疾病
  • 神經病
  • 心血管疾病
  • 其他疾病和適應症

第 9 章生物標誌物市場：按應用

  • 簡介
  • 診斷
  • 藥物發現和開發
  • 個性化醫療
  • 疾病風險評估
  • 其他用途

第 10 章生物標誌物市場：按地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太國家
  • 其他國家（行）
    • 拉丁美洲
    • 中東和非洲

第11章競爭格局

  • 簡介
  • 大公司採用的權利收購方式
  • 主要公司的收入份額分析
  • 市場份額分析
  • 公司評估象限
  • 前 25 家公司的競爭基準
    • 公司產品/服務足跡（25 家公司）
    • 公司的區域足跡（25 家公司）
  • 商業評估象限：初創公司/中小企業
  • 初創公司/中小企業的競爭基準
  • 競爭情景和趨勢
    • 產品發布
    • 資本交易
    • 分機

第12章公司簡介

  • 主要公司
    • MERCK KGAA
    • F. HOFFMANN-LA ROCHE LTD.
    • ABBOTT LABORATORIES
    • QIAGEN N.V.
    • THERMO FISHER SCIENTIFIC INC.
    • PERKINELMER, INC.
    • BIO-RAD LABORATORIES, INC.
    • ENZO BIOCHEM, INC.
    • CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
    • EUROFINS SCIENTIFIC
    • MESO SCALE DIAGNOSTICS, LLC
    • STRESSMARQ BIOSCIENCES INC.
    • AGILENT TECHNOLOGIES, INC.
    • JOHNSON & JOHNSON
    • DIAMETRA
    • SIGNOSIS, INC.
  • 其他企業
    • SINGULEX, INC.
    • BIOMERIEUX SA
    • CISBIO BIOASSAYS
    • EKF DIAGNOSTICS HOLDINGS, PLC
    • MICROCONSTANTS, INC.
    • NORTHEAST BIOANALYTICAL LABORATORIES LLC.
    • JSR LIFE SCIENCES, LLC
    • BIOAGILYTIX LABS
    • CELERION

第13章 附錄

簡介目錄
Product Code: BT 2120

The global biomarkers market is expected to reach USD 104.0 billion in 2028 from USD 59.1 billion in 2023 at a CARG of 12.0%. Factors responsible for the growth in the biomarkers market are mainly factors such as the growing importance of diagnostics, increasing prevalence of cancer and cardiac problems, increasing funds & grants for biomarker research, continuous product innovations, and biomarker advancements. However, factors such as time-consuming process of biomarker validation, high cost, and difficulty in developing assays are hampering the growth of the market.

"During the forecast period, the cancer segment of by disease indications segment, accounted for the largest growing segment of the biomarkers market."

Based on disease indication, the biomarkers market is divided into infectious diseases, neurological disorders, immunological disorders, cancer, cardiovascular disorders, and other disease indications. During the forecast period (2023-2028), the cancer segment is expected to be the fastest-growing segment in the biomarkers market. In the future, the cancer biomarkers are expected to be further boosted by a strong pipeline of products from major manufacturers related to cancer biomarkers. Factors responsible for the high growth of the segment includes early management and early detection by cancer biomarkers.

"In 2022, by application, the diagnostics segment accounted for the biggest share of the biomarkers market."

Based on application, the biomarkers market is divided into drug discovery & development, personalized medicine, diagnostics, disease risk assessment, and other applications. In 2022, the diagnostics segment accounted for the largest share of the application segment in the biomarkers market. Factor responsible for the growth in this segment include, the segment will expand as chronic diseases will become more prevalent, and targeted treatment and diagnosis demand will increase. The growing applications of biomarkers is also driving the growth of the diagnostics segment of the biomarkers market.

"In 2022, North America accounted for the largest share of the biomarkers market."

In 2022, North America accounted for the largest share of the market. Factors responsible for the growth of the region includes increasing population suffering from chronic diseases in the region, increasing use of biomarkers in personalized medicine, various organic & inorganic growth strategies adopted by key players with established pharmaceutical companies in this region, increasing applications and advancements in biomarkers. Additionally, the regional government is also focusing on identifying biomarkers for rare neurodegenerative diseases, which will create new opportunities for market.

Breakdown of primaries

The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:

By Respondent- Supply Side- 70%, Demand Side-30%

By Designation- CXOs and Directors- 30%, Executives - 25%, Mangers - 45%

By Region- North America - 40%, Europe - 25%, APAC - 20%, RoW- 15%

The biomarkers market is dominated by a few globally established players such as F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), ENZO BIOCHEM, INC. (US), Charles River Laboratories International, Inc. (US), Eurofins Scientific S.E. (Luxembourg), Meso Scale Diagnostics, LLC. (US), Stressmarq Biosciences (Canada), DiaMetra Srl (Italy), Signosis, Inc. (US), Agilent Technologies, Inc. (US), Johnson & Johnson (US), bioMerieux SA (France), EKF Diagnostics Holdings, Plc (UK), MicroConstants, Inc. (US), NorthEast BioAnalytical Laboratories LLC. (US), JSR Life Sciences, LLC (US), BioAgilytix Labs (US), Celerion (US), Singulex, Inc. (US), and Cisbio Bioassays (France).

Research Coverage:

The report segments the biomarkers market based on region (Asia Pacific, Europe, North America, and Rest of the World), product (consumables services, software), type (safety biomarkers, efficacy biomarkers [predictive biomarkers, surrogate biomarkers, pharmacodynamics biomarkers, prognostic biomarkers], and validation biomarkers, application (diagnostics, drug discovery & development

personalized medicine, disease risk assessment and other applications), and disease indications (cancer, infectious diseases, immunological disorders, neurological disorders, cardiovascular disorders, and other disease indications). The report also provides a comprehensive review of market drivers, restraints opportunities, challenges and trends in the biomarkers market.

Key Benefits of Buying the Report:

The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the biomarkers market and provides them with information on key market drivers, restraints, challenges, and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 BIOMARKERS MARKET SEGMENTATION
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES
    • 1.7.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 2 BIOMARKERS MARKET: RESEARCH DESIGN
    • 2.1.1 SECONDARY RESEARCH
      • 2.1.1.1 Secondary sources
    • 2.1.2 PRIMARY RESEARCH
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Primary sources
      • 2.1.2.3 Breakdown of primaries
    • FIGURE 3 BIOMARKERS MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 BIOMARKERS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
    • FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022
    • FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF ALL BIOMARKER PRODUCTS IN THE MARKET
    • FIGURE 7 KEY INDUSTRY INSIGHTS
    • FIGURE 8 BIOMARKERS MARKET: CAGR PROJECTIONS, 2023-2028
    • FIGURE 9 BIOMARKERS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.4 RESEARCH LIMITATIONS
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RISK ANALYSIS
  • 2.7 RECESSION IMPACT
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)

3 EXECUTIVE SUMMARY

    • FIGURE 11 BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 BIOMARKERS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 BIOMARKERS MARKET, BY DISEASE INDICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 BIOMARKERS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 15 GEOGRAPHICAL SNAPSHOT OF BIOMARKERS MARKET

4 PREMIUM INSIGHTS

  • 4.1 BIOMARKERS MARKET OVERVIEW
    • FIGURE 16 GROWING IMPORTANCE OF COMPANION DIAGNOSTICS EXPECTED TO DRIVE BIOMARKERS MARKET
  • 4.2 ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT & SERVICE AND BY COUNTRY (2022)
    • FIGURE 17 CONSUMABLES ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2022
  • 4.3 BIOMARKERS MARKET, BY REGION, 2022
    • FIGURE 18 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 MARKET DYNAMICS
    • FIGURE 19 BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.1.1 MARKET DRIVERS
      • 5.1.1.1 Growing importance of companion diagnostics
      • 5.1.1.2 Increase in global prevalence of cancer
    • TABLE 2 NUMBER OF NEW CANCER CASES, BY TYPE, 2020-2040
    • TABLE 3 CANCER INCIDENCE, BY REGION (2040)
      • 5.1.1.3 Increase in funds and grants for biomarker research
      • 5.1.1.4 Continuous product innovations
    • TABLE 4 PRODUCT LAUNCHES, 2020-2022
    • 5.1.2 RESTRAINTS
      • 5.1.2.1 High capital investments and lengthy timelines for biomarker development
    • TABLE 5 TIME FRAME FOR BIOMARKER DEVELOPMENT
    • 5.1.3 OPPORTUNITIES
      • 5.1.3.1 Personalized medicine
      • 5.1.3.2 Emerging economies
    • 5.1.4 CHALLENGES
      • 5.1.4.1 Challenges associated with biomarker validation
      • 5.1.4.2 Technical issues related to sample collection and storage
  • 5.2 REGULATORY ASSESSMENT
    • 5.2.1 INTRODUCTION
    • 5.2.2 BIOMARKER QUALIFICATION IN US
    • 5.2.3 BIOMARKER QUALIFICATION IN EUROPE
  • 5.3 VALUE CHAIN ANALYSIS
    • FIGURE 20 BIOMARKERS MARKET: VALUE CHAIN ANALYSIS
  • 5.4 TECHNOLOGICAL ANALYSIS
    • 5.4.1 IMMUNOASSAYS
      • 5.4.1.1 Immunohistochemistry (IHC)
      • 5.4.1.2 Flow cytometry
      • 5.4.1.3 Flow cytometry ELISA
    • 5.4.2 NEXT-GENERATION SEQUENCING (NGS)
    • 5.4.3 POLYMERASE CHAIN REACTION (PCR)
    • 5.4.4 IN SITU HYBRIDIZATION
    • 5.4.5 MICROARRAYS
    • 5.4.6 MASS SPECTROMETRY
  • 5.5 PRICING ANALYSIS
    • TABLE 6 SELLING PRICE OF BIOMARKERS BY TOP PLAYERS
  • 5.6 PATENT ANALYSIS
    • FIGURE 21 PATENT APPLICATIONS FOR BIOMARKERS MARKET, JANUARY 2012-DECEMBER 2022
  • 5.7 BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS
    • FIGURE 22 BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS
    • 5.7.1 KEY INFLUENCERS
  • 5.8 ECOSYSTEM ANALYSIS
    • TABLE 7 BIOMARKERS MARKET: SUPPLY CHAIN ECOSYSTEM
  • 5.9 KEY CONFERENCES AND EVENTS, 2023-2024
    • TABLE 8 BIOMARKERS MARKET: LIST OF CONFERENCES AND EVENTS
  • 5.10 PORTER'S FIVE FORCES ANALYSIS
    • 5.10.1 IMPACT OF PORTER'S FIVE FORCES ON BIOMARKERS MARKET
    • 5.10.2 INTENSITY OF COMPETITIVE RIVALRY
    • 5.10.3 BARGAINING POWER OF SUPPLIERS
    • 5.10.4 BARGAINING POWER OF BUYERS
    • 5.10.5 THREAT OF SUBSTITUTES
    • 5.10.6 THREAT OF NEW ENTRANTS
  • 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOMARKERS
    • 5.11.2 BIOMARKERS MARKET: BUYING CRITERIA
    • FIGURE 24 KEY BUYING CRITERIA FOR END USERS
  • 5.12 ECOSYSTEM ANALYSIS OF BIOMARKERS MARKET
    • FIGURE 25 BIOMARKERS MARKET: ECOSYSTEM ANALYSIS
    • 5.12.1 ROLE IN ECOSYSTEM
  • 5.13 REVENUE SHIFT FOR BIOMARKERS MARKET
    • FIGURE 26 BIOMARKERS MARKET: REVENUE SHIFT

6 BIOMARKERS MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 9 BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • 6.2 CONSUMABLES
    • 6.2.1 NEED FOR HIGH-FREQUENCY PURCHASE OF CONSUMABLES TO DRIVE MARKET GROWTH
    • TABLE 10 BIOMARKER CONSUMABLES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 11 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 12 EUROPE: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 13 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 14 ROW: BIOMARKER CONSUMABLES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.3 SERVICES
    • 6.3.1 GRADUAL SHIFT FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING OF SERVICES TO SUPPORT MARKET GROWTH
    • TABLE 15 BIOMARKER SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 16 NORTH AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 17 EUROPE: BIOMARKER SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 18 ASIA PACIFIC: BIOMARKER SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 19 ROW: BIOMARKER SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.4 SOFTWARE
    • 6.4.1 INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO SUPPORT MARKET GROWTH
    • TABLE 20 BIOMARKER SOFTWARE MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 21 NORTH AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 22 EUROPE: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 23 ASIA PACIFIC: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 24 ROW: BIOMARKER SOFTWARE MARKET, BY REGION, 2021-2028 (USD MILLION)

7 BIOMARKERS MARKET, BY TYPE

  • 7.1 INTRODUCTION
    • TABLE 25 BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 7.2 EFFICACY BIOMARKERS
    • TABLE 26 EFFICACY BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 27 EFFICACY BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 28 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 29 EUROPE: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 30 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 31 ROW: PREDICTIVE BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 7.2.1 PREDICTIVE BIOMARKERS
      • 7.2.1.1 Wide applications of predictive biomarkers in personalized medicine and companion diagnostics to drive market
    • TABLE 32 PREDICTIVE BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 33 NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 34 EUROPE: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 35 ASIA PACIFIC: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 36 ROW: PREDICTIVE BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 7.2.2 SURROGATE BIOMARKERS
      • 7.2.2.1 Use of surrogate biomarkers helps accelerate drug development and shorten timelines for regulatory approval
    • TABLE 37 SURROGATE BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 38 NORTH AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 39 EUROPE: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 40 ASIA PACIFIC: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 41 ROW: SURROGATE BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 7.2.3 PHARMACODYNAMIC BIOMARKERS
      • 7.2.3.1 Increasing utilization of pharmacodynamic biomarkers in selection and optimization of drug doses to boost market
    • TABLE 42 PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 43 NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 44 EUROPE: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 45 ASIA PACIFIC: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 46 ROW: PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 7.2.4 PROGNOSTIC BIOMARKERS
      • 7.2.4.1 Prognostic biomarkers help predict recurrence of diseases
    • TABLE 47 PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 48 NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 49 EUROPE: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 50 ASIA PACIFIC: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 51 ROW: PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 7.3 SAFETY BIOMARKERS
    • 7.3.1 WIDE APPLICATIONS OF SAFETY BIOMARKERS IN DRUG DISCOVERY & DEVELOPMENT TO FUEL MARKET GROWTH
    • TABLE 52 SAFETY BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 53 NORTH AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 54 EUROPE: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 55 ASIA PACIFIC: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 56 ROW: SAFETY BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 7.4 VALIDATION BIOMARKERS
    • 7.4.1 VALIDATION BIOMARKERS ENABLE EVALUATION OF DIAGNOSTIC SYSTEMS
    • TABLE 57 VALIDATION BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 58 NORTH AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 59 EUROPE: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 60 ASIA PACIFIC: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 61 ROW: VALIDATION BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)

8 BIOMARKERS MARKET, BY DISEASE INDICATION

  • 8.1 INTRODUCTION
    • TABLE 62 BIOMARKERS MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
  • 8.2 CANCER
    • 8.2.1 INCREASING ADOPTION OF BIOMARKERS IN CANCER RESEARCH AND DIAGNOSIS TO DRIVE MARKET
    • TABLE 63 LIST OF FDA-APPROVED BIOMARKERS FOR DIFFERENT TYPES OF CANCER
    • TABLE 64 BIOMARKERS MARKET FOR CANCER, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 65 NORTH AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 66 EUROPE: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 67 ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 68 ROW: BIOMARKERS MARKET FOR CANCER, BY REGION, 2021-2028 (USD MILLION)
  • 8.3 INFECTIOUS DISEASES
    • 8.3.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE DEMAND FOR BIOMARKERS
    • TABLE 69 BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 70 NORTH AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 71 EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 72 ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 73 ROW: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
  • 8.4 IMMUNOLOGICAL DISORDERS
    • 8.4.1 INCREASING ADOPTION OF BIOMARKERS FOR VARIOUS IMMUNOLOGICAL DISORDERS TO DRIVE MARKET
    • TABLE 74 BIOMARKERS FOR IMMUNOLOGICAL DISORDERS
    • TABLE 75 BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 76 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 77 EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 78 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 79 ROW: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)
  • 8.5 NEUROLOGICAL DISORDERS
    • 8.5.1 IMMUNOASSAYS WIDELY USED IN DIAGNOSIS OF NEUROLOGICAL DISORDERS
    • TABLE 80 BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 81 NORTH AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 82 EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 83 ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 84 ROW: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)
  • 8.6 CARDIOVASCULAR DISORDERS
    • 8.6.1 GROWING PREVALENCE OF CVD TO INCREASE DEMAND FOR CARDIAC BIOMARKERS
    • TABLE 85 BIOMARKERS FOR CARDIOVASCULAR DISORDERS
    • TABLE 86 BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 87 NORTH AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 88 EUROPE: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 89 ASIA PACIFIC: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 90 ROW: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2021-2028 (USD MILLION)
  • 8.7 OTHER DISEASE INDICATIONS
    • TABLE 91 BIOMARKERS FOR RENAL DISORDERS
    • TABLE 92 BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 93 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 94 EUROPE: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 95 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 96 ROW: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2021-2028 (USD MILLION)

9 BIOMARKERS MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 97 BIOMARKERS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 9.2 DIAGNOSTICS
    • 9.2.1 INCREASING USE OF BIOMARKERS FOR DIAGNOSIS OF VARIOUS DISEASES TO DRIVE GROWTH
    • TABLE 98 BIOMARKERS MARKET FOR DIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 99 NORTH AMERICA: BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 100 EUROPE: BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 101 ASIA PACIFIC: BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 102 ROW: BIOMARKERS MARKET FOR DIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)
  • 9.3 DRUG DISCOVERY & DEVELOPMENT
    • 9.3.1 BIOMARKERS PLAY KEY ROLE AS BIOLOGICAL INDICATORS IN DEVELOPMENT OF NEW DRUGS
    • TABLE 103 BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 104 NORTH AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 105 EUROPE: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 106 ASIA PACIFIC: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 107 ROW: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.4 PERSONALIZED MEDICINE
    • 9.4.1 INCREASING APPLICATIONS OF BIOMARKERS IN PERSONALIZED MEDICINE TO DRIVE MARKET
    • TABLE 108 SELECTED PERSONALIZED MEDICINE DRUGS AND RELEVANT BIOMARKERS
    • TABLE 109 BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 110 NORTH AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 111 EUROPE: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 112 ASIA PACIFIC: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 113 ROW: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.5 DISEASE RISK ASSESSMENT
    • 9.5.1 BIOMARKERS WIDELY USED FOR TOXICITY CHARACTERIZATION IN DISEASE DIAGNOSIS AND DRUG DEVELOPMENT PROCESSES
    • TABLE 114 BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 115 NORTH AMERICA: BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 116 EUROPE: BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 117 ASIA PACIFIC: BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 118 ROW: BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY REGION, 2021-2028 (USD MILLION)
  • 9.6 OTHER APPLICATIONS
    • TABLE 119 BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 120 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 121 EUROPE: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 122 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 123 ROW: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)

10 BIOMARKERS MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 124 BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 27 NORTH AMERICA: BIOMARKERS MARKET SNAPSHOT
    • TABLE 125 NORTH AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 126 NORTH AMERICA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 127 NORTH AMERICA: BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 128 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 129 NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 130 NORTH AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 US expected to dominate biomarkers market in North America during forecast period
    • TABLE 131 US: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 132 US: BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 133 US: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 134 US: BIOMARKERS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 135 US: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Increasing incidence of cancer to drive growth of biomarker research
    • TABLE 136 CANADA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 137 CANADA: BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 138 CANADA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 139 CANADA: BIOMARKERS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 140 CANADA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • 10.2.3 NORTH AMERICA: RECESSION IMPACT
  • 10.3 EUROPE
    • TABLE 141 EUROPE: BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 142 EUROPE: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 143 EUROPE: BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 144 EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 145 EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 146 EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Increase in government funding for biomarker research to drive market growth
    • TABLE 147 GERMANY: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 148 GERMANY: BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 149 GERMANY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 150 GERMANY: BIOMARKERS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 151 GERMANY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 Government funding and strategic collaborations with biotech firms to boost adoption of biomarkers
    • TABLE 152 UK: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 153 UK: BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 154 UK: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 155 UK: BIOMARKERS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 156 UK: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Increasing government investments in genomics and proteomics research to drive market growth
    • TABLE 157 FRANCE: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 158 FRANCE: BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 159 FRANCE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 160 FRANCE: BIOMARKERS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 161 FRANCE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • 10.3.4 ITALY
      • 10.3.4.1 Increasing life science R&D funding to drive market growth
    • TABLE 162 ITALY: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 163 ITALY: BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 164 ITALY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 165 ITALY: BIOMARKERS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 166 ITALY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • 10.3.5 SPAIN
      • 10.3.5.1 Growing focus on cancer biomarkers to propel market growth
    • TABLE 167 SPAIN: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 168 SPAIN: BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 169 SPAIN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 170 SPAIN: BIOMARKERS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 171 SPAIN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • 10.3.6 REST OF EUROPE
    • TABLE 172 REST OF EUROPE: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 173 REST OF EUROPE: BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 174 REST OF EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 175 REST OF EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 176 REST OF EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • 10.3.7 EUROPE: RECESSION IMPACT
  • 10.4 ASIA PACIFIC
    • TABLE 177 ASIA PACIFIC: BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 178 ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 179 ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 180 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 181 ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 182 ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • 10.4.1 CHINA
      • 10.4.1.1 Increasing burden of diseases and growing focus on development of novel drugs to drive demand for biomarkers
    • TABLE 183 CHINA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 184 CHINA: BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 185 CHINA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 186 CHINA: BIOMARKERS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 187 CHINA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • 10.4.2 JAPAN
      • 10.4.2.1 Strategic collaborations with leading pharmaceutical companies to drive market
    • TABLE 188 JAPAN: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 189 JAPAN: BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 190 JAPAN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 191 JAPAN: BIOMARKERS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 192 JAPAN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Growing prevalence of target diseases expected to support biomarkers market
    • TABLE 193 INDIA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 194 INDIA: BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 195 INDIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 196 INDIA: BIOMARKERS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 197 INDIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • 10.4.4 REST OF ASIA PACIFIC
    • TABLE 198 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 199 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 200 REST OF ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 201 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 202 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • 10.4.5 ASIA PACIFIC: RECESSION IMPACT
  • 10.5 REST OF THE WORLD
    • TABLE 203 ROW: BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 204 ROW: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 205 ROW: BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 206 ROW: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 207 ROW: BIOMARKERS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 208 ROW: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • 10.5.1 LATIN AMERICA
      • 10.5.1.1 Research funding and rising awareness of advanced sequencing technologies to drive market
    • TABLE 209 LATIN AMERICA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 210 LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 211 LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 212 LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 213 LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • 10.5.2 LATIN AMERICA: RECESSION IMPACT
    • 10.5.3 MIDDLE EAST & AFRICA
      • 10.5.3.1 Increasing focus on proteomics and genomics research to support market growth
    • TABLE 214 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 215 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 216 MIDDLE EAST & AFRICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 217 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 218 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • 10.5.4 MIDDLE EAST & AFRICA: RECESSION IMPACT

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
    • FIGURE 28 BIOMARKERS MARKET: STRATEGIES ADOPTED
  • 11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 29 REVENUE ANALYSIS OF KEY COMPANIES OVER LAST THREE YEARS (2019-2022)
  • 11.4 MARKET SHARE ANALYSIS
    • FIGURE 30 BIOMARKERS MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
    • TABLE 219 BIOMARKERS MARKET: DEGREE OF COMPETITION
  • 11.5 COMPANY EVALUATION QUADRANT
    • FIGURE 31 BIOMARKERS MARKET: COMPANY EVALUATION MATRIX, 2022
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
  • 11.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
    • 11.6.1 PRODUCT & SERVICE FOOTPRINT OF COMPANIES (25 COMPANIES)
    • TABLE 220 BIOMARKERS MARKET: PRODUCT & SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS
    • 11.6.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
    • TABLE 221 BIOMARKERS MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
  • 11.7 COMPANY EVALUATION QUADRANT: START-UPS/SMES
    • FIGURE 32 BIOMARKERS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
    • 11.7.1 PROGRESSIVE COMPANIES
    • 11.7.2 STARTING BLOCKS
    • 11.7.3 RESPONSIVE COMPANIES
    • 11.7.4 DYNAMIC COMPANIES
  • 11.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
    • TABLE 222 BIOMARKERS MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
    • TABLE 223 BIOMARKERS MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
  • 11.9 COMPETITIVE SCENARIOS AND TRENDS
    • 11.9.1 PRODUCT LAUNCHES
    • TABLE 224 BIOMARKERS MARKET: PRODUCT LAUNCHES, JANUARY 2020-DECEMBER 2022
    • 11.9.2 DEALS
    • TABLE 225 BIOMARKERS MARKET: DEALS, JANUARY 2020-DECEMBER 2022
    • 11.9.3 EXPANSIONS
    • TABLE 226 BIOMARKERS MARKET: EXPANSIONS, JANUARY 2020-DECEMBER 2022

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS

(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*

    • 12.1.1 MERCK KGAA
    • TABLE 227 MERCK KGAA: BUSINESS OVERVIEW
    • FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2021)
    • TABLE 228 OTHER DEVELOPMENTS
    • 12.1.2 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 229 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
    • FIGURE 34 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)
    • 12.1.3 ABBOTT LABORATORIES
    • TABLE 230 ABBOTT LABORATORIES: BUSINESS OVERVIEW
    • FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
    • 12.1.4 QIAGEN N.V.
    • TABLE 231 QIAGEN N.V.: BUSINESS OVERVIEW
    • FIGURE 36 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
    • 12.1.5 THERMO FISHER SCIENTIFIC INC.
    • TABLE 232 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
    • FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021)
    • 12.1.6 PERKINELMER, INC.
    • TABLE 233 PERKINELMER, INC.: BUSINESS OVERVIEW
    • FIGURE 38 PERKINELMER, INC.: COMPANY SNAPSHOT (2021)
    • 12.1.7 BIO-RAD LABORATORIES, INC.
    • TABLE 234 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
    • FIGURE 39 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
    • 12.1.8 ENZO BIOCHEM, INC.
    • TABLE 235 ENZO BIOCHEM, INC.: BUSINESS OVERVIEW
    • FIGURE 40 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.9 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
    • TABLE 236 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW
    • FIGURE 41 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2021)
    • 12.1.10 EUROFINS SCIENTIFIC
    • TABLE 237 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 42 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021)
    • 12.1.11 MESO SCALE DIAGNOSTICS, LLC
    • TABLE 238 MESO SCALE DIAGNOSTICS, LLC: BUSINESS OVERVIEW
    • 12.1.12 STRESSMARQ BIOSCIENCES INC.
    • TABLE 239 STRESSMARQ BIOSCIENCES INC.: BUSINESS OVERVIEW
    • 12.1.13 AGILENT TECHNOLOGIES, INC.
    • TABLE 240 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
    • FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021)
    • 12.1.14 JOHNSON & JOHNSON
    • TABLE 241 JOHNSON & JOHNSON: BUSINESS OVERVIEW
    • FIGURE 44 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2021)
    • 12.1.15 DIAMETRA
    • TABLE 242 DIAMETRA: BUSINESS OVERVIEW
    • 12.1.16 SIGNOSIS, INC.
    • TABLE 243 SIGNOSIS, INC.: BUSINESS OVERVIEW
  • 12.2 OTHER PLAYERS
    • 12.2.1 SINGULEX, INC.
    • TABLE 244 SINGULEX, INC.: BUSINESS OVERVIEW
    • 12.2.2 BIOMERIEUX SA
    • TABLE 245 BIOMERIEUX SA: BUSINESS OVERVIEW
    • 12.2.3 CISBIO BIOASSAYS
    • TABLE 246 CISBIO BIOASSAYS: BUSINESS OVERVIEW
    • 12.2.4 EKF DIAGNOSTICS HOLDINGS, PLC
    • TABLE 247 EKF DIAGNOSTICS HOLDINGS, PLC: BUSINESS OVERVIEW
    • 12.2.5 MICROCONSTANTS, INC.
    • TABLE 248 MICROCONSTANTS, INC.: BUSINESS OVERVIEW
    • 12.2.6 NORTHEAST BIOANALYTICAL LABORATORIES LLC.
    • TABLE 249 NORTHEAST BIOANALYTICAL LABORATORIES LLC.: BUSINESS OVERVIEW
    • 12.2.7 JSR LIFE SCIENCES, LLC
    • TABLE 250 JSR LIFE SCIENCES, LLC: BUSINESS OVERVIEW
    • 12.2.8 BIOAGILYTIX LABS
    • TABLE 251 BIOAGILYTIX LABS: BUSINESS OVERVIEW
    • 12.2.9 CELERION
    • TABLE 252 CELERION: BUSINESS OVERVIEW
  • Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS